|
|
|
|
| LEADER |
01578nam a2200241 u 4500 |
| 001 |
EB002000691 |
| 003 |
EBX01000000000000001163592 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
210907 r ||| eng |
| 100 |
1 |
|
|a McDonagh, Marian S.
|
| 245 |
0 |
0 |
|a Drug class review on disease-modifying drugs for multiple sclerosis
|h Elektronische Ressource
|b final report
|c Marian S. McDonagh ... [et al.]
|
| 260 |
|
|
|a Portland, Or.
|b Oregon Health & Science University, Evidence-Based Practice Center
|c c2007, 2007
|
| 300 |
|
|
|a PDF file (70 p.)
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 710 |
2 |
|
|a Oregon Health & Science University
|b Evidence-based Practice Center
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a Drug class reviews
|
| 500 |
|
|
|a "July 2007."
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK10578
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a Multiple Sclerosis (MS) is a chronic, autoimmune disease of the central nervous system (CNS) that affects about 250,000 people in the United States, although estimates are as high as 400,000 people. The treatment of MS involves acute relapse treatment with corticosteroids, symptom management with appropriate agents and disease modification with disease-modifying drugs (DMD). These agents modify the immune response that occurs in MS through various immunomodulatory or immunosuppressive effects. The purpose of this review is to compare the effectiveness and safety of different disease-modifying drugs for the treatment of MS.
|